[Skip to Navigation]
Sign In
Comment & Response
April 2016

Pregnancy Rate and Preservation of Cyclic Ovarian Function With Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy—Reply

Author Affiliations
  • 1Erasme Hospital, Research Laboratory on Human Reproduction, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium
  • 2Division of Reproductive Medicine and Laboratory of Molecular Reproduction & Fertility Preservation, Department of Obstetrics and Gynecology, New York Medical College, Valhalla
  • 3Innovation Institute for Fertility Preservation and In Vitro Fertilization, New York, New York
JAMA Oncol. 2016;2(4):546-547. doi:10.1001/jamaoncol.2015.5743

In Reply Dr Blumenfeld’s letter underscores our sentiment that superficial assessment of the studies on the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preserving fertility could lead to inaccurate conclusions.

Dr Blumenfeld cited his retrospective study that had numerous weaknesses, including the lack of uniformity in patient selection, which were highlighted in the commentary of Del Mastro and Lambertini.1 Therefore, the results cannot be considered as evidence for the efficacy of GnRHa cotreatment.

Add or change institution